Furthermore, in cancer patients, higher expression of ADAM17 significantly decreased patient survival in overall survival (OS) in four types of cancers, which was supported by our systematic review results that 7.15% of COVID-19 patients (5,068) had cancer coincidental situations, and the rate of more severe events of COVID-19 patients with malignant cancers (33.33%) presented a higher trend than that for all COVID-19 patients (16.09%) with a significant difference (50). The gene discussed is ADAM17; the disease is cancer.